WuXi STA, a subsidiary of WuXi AppTec, is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life science industry, with global operations. As a premier Contract Research, Development and Manufacturing Organization (CRDMO), WuXi STA offers our worldwide partners efficient, flexible and high-quality solutions for integrated CMC (Chemical, Manufacturing, and Control) from preclinical to commercial.
WuXi STA peptide platform provides comprehensive CRDMO services from drug discovery to commercial manufacturing, combining traditional CRO (Contract Research Organization), CDMO (Contract Development and Manufacturing Organization) and CMO (Contract Manufacturing Organization) services under one roof.
Our vertically integrated peptide platform covers from unnatural amino acid, conjugate, API to drug product, coupled with comprehensive analytical support and CMC writing service, supporting our customers bring their peptide therapeutics to market faster.
From peptide discovery to development and manufacturing, including API, drug product, analytical and CMC dossier preparation, all within WuXi STA
Peptide chemistry expertise in linear & cyclic peptide, peptide mimics synthesis, peptide library synthesis and peptide modification
Advanced technologies including both solid phase and liquid phase chemistry
2,500+ amino acid derivatives in category product library
Payload and linker synthesis, conjugation chemistry with peptide, DNA, RNA, PMO or antibody
1,000+ peptide customers worldwide since 2009
600+ peptide scientists (R&D, analytical and manufacturing)
10,000+ peptide discovery projects with 98%+ success rate every year
40+ peptide CMC projects since 2018
White paper: Picking the right cdmo partner for integrated and accelerated peptide therapeutic development
WuXi AppTec Plans to Build a New Site in Singapore, Better Serving Global Partners and Advancing Healthcare Innovation